A phase 1/2 trial of VBC108 in advanced solid tumours, run by VelaVigo Bio Inc, now recruiting.
First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors is a phase 1/2 interventional study registered as NCT07700160 by VelaVigo Bio Inc, with 230 participants planned, started 2026-07-30 and due to reach its primary completion in 2029-07-07. Interventions recorded: VBC108.
Shares VelaVigo, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares VelaVigo, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.